NAMAPA
Latest Content
As more adalimumab biosimilars are poised to enter the market, manufacturers, payers, and patient advocates are preparing to navigate potentially turbulent waters.
Eight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.
Health care advocates provide a vital service for patients who are managing chronic conditions.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Afibercept-Boav as Biosimilar to Afibercept for Diabetic Macular Edema
2
FDA Approves Risperidone Injection for Bipolar I Disorder in Adults
3
Vaccine Messaging for Teens Should Tailor to Personal Perspectives
4
American Pharmacists Month: Students Seeking Both Common, Non-Traditional Pharmacy Careers
5
